Japanese cedar pollinosis
Conditions
Interventions
1)Japanese cedar pollen allergy relief rice 20g intake group (allergy rerief rice 20g plus pracebo rice 30g once a day, for 24 weeks, 15 cases)
2)the same 5g intake group (allergy rerief rice 5g plus
Sponsors
Osaka Habikino Medical Center
Department of Clinical Application of Biologics, Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)those who have presented with symptoms related allergic rhinitis such as sneezing, nasal discharge, obstruction and eye itching for at least 2 continuous years, consistent with the cedar pollen season 2)those whose Japanese cedar pollen allergen-specific IgE antibody titer show class the 2 or more (measured by AlaSTAT 3g method) 3)those whose Japanese cypress pollen-specific IgE antibody titer show the class 4 or less(AlaSTAT 3g) 4)those who live or work in Osaka prefecture and consented to research participation by the document from the person obtained 5)those who can comply with not to transfer the test product to a third party
Exclusion criteria
Exclusion criteria: 1)those whom Principal Investigator or the sharing researchers have determined inappropriate 2)those who suffer from rice allergy or have a history of rice allergy 3)those whose pets (dogs, cats) and house dust and mite-specific IgE antibody titers show the class of 5 or more, ond who are breeding a pet. 4)those whose house dust and mite-specific IgE antibody titer, swow higher than the cedar pollen-specific IgE antibody titers 5)those who have received immunotherapy for cedar pollen, or have the schedule 6)those who suffer from some serious disease with disease activity, therefore, are judged unsuitable for enrolement by the clinician 7)those who are or planning to become pregnant or in the process of breast-feeding during the clinical reseach 8)those who are participating in other clinical research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptoms of cedar pollen allergy from 12 weeks to 24 weeks after the start of ingestion | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)use of the therapeutic agent and QOL for cedar pollen allergy from 12 weeks to 24 weeks after the start of ingestion 2)Adverse events from the start to the end of ingestion | — |
Countries
Japan
Contacts
Public ContactShoji Hashimoto
Osaka Prefectural Medical Center for Respiratory and Allergic Diseases Department of Clinical Reseach & Development
Outcome results
None listed